Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | recruiting | Phase 4 | 100 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT04296305 | Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain | active not recruiting | Phase 4 | 84 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07405086 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study |
| recruiting |
| Phase 4 |
| 160 |
| OHSU Knight Cancer InstituteOTHER |
| 1 |
| Jun 12, 2026 |
| clinicaltrials |
| NCT07590648 | Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia(E-STOP2) | not yet recruiting | Phase 4 | 136 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04745910 | Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome | completed | Phase 4 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05203172 | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | recruiting | Phase 4 | 46 | PfizerINDUSTRY | 17 | Apr 7, 2026 | clinicaltrials |
| NCT05525767 | Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer | recruiting | Phase 4 | 75 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT03229200 | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | active not recruiting | Phase 4 | 297 | Pharmacyclics Switzerland GmbHINDUSTRY | 17 | Oct 30, 2025 | clinicaltrials |
| NCT04319198 | Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy | completed | Phase 4 | 25 | Gilead SciencesINDUSTRY | 3 | Sep 30, 2025 | clinicaltrials |
| NCT06834386 | Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients | withdrawn | Phase 4 | 0 | Mayo ClinicOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT06824792 | Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent System(SINGULARITY) | not yet recruiting | Phase 4 | 3,000 | NING LIOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06408688 | Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors(ISCA-CHECK) | recruiting | Phase 4 | 100 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04078152 | Durvalumab Long-Term Safety and Efficacy Study(WAVE) | completed | Phase 4 | 163 | AstraZenecaINDUSTRY | 31 | Dec 20, 2024 | clinicaltrials |
| NCT05054998 | Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases | completed | Phase 4 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT02688881 | Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors | completed | Phase 4 | 6 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT02691793 | Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors | completed | Phase 4 | 1 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04475705 | Propofol vs Sevo for Paediatric Tumor Surgery | recruiting | Phase 4 | 100 | Hong Kong Children's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT02095951 | Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection | completed | Phase 4 | 30 | Children's Hospital of MichiganOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT00944372 | Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors | terminated | Phase 4 | 150 | MallinckrodtINDUSTRY | 1 | Sep 9, 2016 | clinicaltrials |
| NCT02805166 | PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy | completed | Phase 4 | 420 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 17, 2016 | clinicaltrials |
| NCT02101164 | Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease | withdrawn | Phase 4 | 0 | AmgenINDUSTRY | 0 | Feb 18, 2015 | clinicaltrials |
| NCT01994031 | Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments | unknown | Phase 4 | 36 | Nanjing Luye Sike Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 27, 2014 | clinicaltrials |
| NCT00378937 | Oxycodone or Standard Pain Therapy in Treating Patients With Cancer Pain | completed | Phase 4 | 30 | University Hospitals Bristol and Weston NHS Foundation TrustOTHER | 0 | Aug 2, 2013 | clinicaltrials |
| NCT00003252 | Amifostine in Treating Patients With Cancer Who Have Neurological Changes Caused by Chemotherapy | completed | Phase 4 | — | Rush North Shore Medical CenterOTHER | 1 | Mar 26, 2013 | clinicaltrials |
| NCT00808184 | Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype | completed | Phase 4 | 25 | National University Hospital, SingaporeOTHER | 1 | Nov 1, 2012 | clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials